| E-mail： huangkai@whu.edu.cn |
Biography
Huang Kai is a Changjiang Distinguished Professor of the Ministry of Education, Chief Physician and Doctoral Supervisor. He currently serves as the Secretary of the Party Committee of Renmin Hospital of Wuhan University and Director of the Hubei Provincial Clinical Research Center for Metabolic Cardiovascular Diseases. His primary research focus on metabolic and cardiovascular diseases.He has presided over multiple major national and provincial-level research projects and has published over 90 high-impact SCI papers as the first or corresponding author (including co-author). He has been awarded one first prize of the Hubei Provincial Science and Technology Progress Award, one first prize of the Chinese Medical Science and Technology Award, and one first prize of the Hubei Provincial Natural Science Award, respectively, as the first completer.
Research
Huang Lab has long been dedicated to applied basic research, epidemiological studies, and prevention strategies related to metabolic disorders and associated cardiovascular diseases. The main research directions include:
Epidemiological studies of chronic metabolic diseases: Systematically delineate the epidemiological characteristics, population distribution patterns, and influencing factors of these diseases to provide an epidemiological basis for disease prevention and control.
Research on the pathogenesis of metabolism-related diseases: Focus on investigating the pathophysiological mechanisms of obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), diabetes, and atherosclerotic cardiovascular diseases (ASCVD), unveiling core molecular targets and regulatory networks involved in disease development and progression.
Research on precision treatment strategies for atherosclerosis: Building on mechanistic discoveries, develop and optimize precision diagnostic technologies and targeted therapeutic approaches for atherosclerosis, promoting clinical translation and application
Representative Publications
1. Zilong Chen#, Can Chen#, Yichen Wu, Yinxue Xia, Ruijie Luo, Jiangcheng Shu, Long Chen, Zhaohui Wang#, Cheng Wang*, Kai Huang*. EBBP-Mediated Integrated Stress Response Attenuates Anthracycline-Induced Cardiotoxicity by Inhibiting the Ferroptosis of Cardiomyocytes. Adv Sci (Weinh). 2025 Aug;12(32):e02726.
2. Wenjing Xu#, Yichen Wu#, Ruiqi Mao#, Yujie Jia, Hao Jiang , Fengxiao Zhang, Dan Huang, Ximiao He , Cheng Wang* and Kai Huang*. Poly(ADP-ribose) polymerase 1 orchestrates vascular smooth muscle cell homeostasis in arterial disease. Exp Mol Med. 2025 Aug;57(8):1686-1699.
3. Liuye Yang#, Pengchao Wang#, Kaiyuan Liu#, Bing Liu, Jingbo Zhu, Fengcen L, Mingfa Ai, Xiaoguang Li, Minglu Liang, Kai Huang*, Meng Du*. Long noncoding RNA Nron and its functional motif modulate macrophage-mediated inflammatory response. J Adv Res. 2025 Aug 22:S2090-1232(25)00647-2.
4. Qin H#, Zhong Y#, Huang J, Miao Y, Du M*, Huang K*.TRIM56 Promotes White Adipose Tissue Browning to Attenuate Obesity by Degrading TLE3. Adv Sci (Weinh). 2025 Apr;12(13):e2414073.
5. Wang C#*, Xu W#, Jiang S#, Wu Y, Shu J, Gao X, Huang K*.β-Hydroxybutyrate Facilitates Postinfarction Cardiac Repair via Targeting PHD2. Circ Res. 2025 Mar 28;136(7):704-718
6. Tian Y#, Qiu Z, Wang F, Deng S, Wang Y, Wang Z, Yin P, Huo Y, Zhou M*, Liu G*, Huang K *.Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in China: A National Study. Diabetes Care. 2024 Nov 1;47(11):1969-1977.
7. Wang C#*, Zhang W, Xu W, Liu Z, Huang K*. AMP-activated protein kinase α1 phosphorylates PHD2 to maintain systemic iron homeostasis. Clin Transl Med. 2022 May;12(5):e854.
8. Wang C#*, Dai X, Wu S, Xu W, Song P, Huang K*, Zou MH*. FUNDC1-dependent mitochondria-associated endoplasmic reticulum membranes are involved in angiogenesis and neoangiogenesis. Nat Commun. 2021 May 10;12(1):2616.
9. Du M#*, Wang X, Yuan L, Liu B, Mao X, Huang D, Yang L, Huang K, Zhang F, Wang Y, Luo X, Wang C, Peng J, Liang M, Huang D, Huang K*. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice. J Hepatol. 2020 Dec;73(6):1333-1346
10. Wang C#*, Xu W, Chao Y, Liang M, Zhang F, Huang K*.E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis. Adv Sci (Weinh). 2020 Aug 26;7(20):2001800.
